US5776093A
(en)
|
1985-07-05 |
1998-07-07 |
Immunomedics, Inc. |
Method for imaging and treating organs and tissues
|
US6168778B1
(en)
|
1990-06-11 |
2001-01-02 |
Nexstar Pharmaceuticals, Inc. |
Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
|
US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
US6762290B1
(en)
|
1999-07-29 |
2004-07-13 |
Gilead Sciences, Inc. |
High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
|
CA2131528C
(en)
*
|
1992-03-05 |
2004-07-13 |
Philip E. Thorpe |
Methods and compositions for targeting the vasculature of solid tumors
|
US5965132A
(en)
*
|
1992-03-05 |
1999-10-12 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
US5877289A
(en)
*
|
1992-03-05 |
1999-03-02 |
The Scripps Research Institute |
Tissue factor compositions and ligands for the specific coagulation of vasculature
|
US6093399A
(en)
*
|
1992-03-05 |
2000-07-25 |
Board Of Regents, The University Of Texas System |
Methods and compositions for the specific coagulation of vasculature
|
US5660827A
(en)
*
|
1992-03-05 |
1997-08-26 |
Board Of Regents, The University Of Texas System |
Antibodies that bind to endoglin
|
US6004555A
(en)
*
|
1992-03-05 |
1999-12-21 |
Board Of Regents, The University Of Texas System |
Methods for the specific coagulation of vasculature
|
US6036955A
(en)
*
|
1992-03-05 |
2000-03-14 |
The Scripps Research Institute |
Kits and methods for the specific coagulation of vasculature
|
US6749853B1
(en)
|
1992-03-05 |
2004-06-15 |
Board Of Regents, The University Of Texas System |
Combined methods and compositions for coagulation and tumor treatment
|
US6824777B1
(en)
|
1992-10-09 |
2004-11-30 |
Licentia Ltd. |
Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
|
US5776755A
(en)
*
|
1992-10-09 |
1998-07-07 |
Helsinki University Licensing, Ltd. |
FLT4, a receptor tyrosine kinase
|
US6107046A
(en)
*
|
1992-10-09 |
2000-08-22 |
Orion Corporation |
Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
|
US5981569A
(en)
*
|
1992-11-13 |
1999-11-09 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
|
US5763441A
(en)
*
|
1992-11-13 |
1998-06-09 |
Sugen, Inc. |
Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
|
US5712395A
(en)
*
|
1992-11-13 |
1998-01-27 |
Yissum Research Development Corp. |
Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
|
US5792771A
(en)
*
|
1992-11-13 |
1998-08-11 |
Sugen, Inc. |
Quinazoline compounds and compositions thereof for the treatment of disease
|
US6177401B1
(en)
|
1992-11-13 |
2001-01-23 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften |
Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
|
CA2158745C
(en)
|
1993-03-25 |
2007-06-19 |
Richard L. Kendall |
Inhibitor of vascular endothelial cell growth factor
|
US6306829B1
(en)
|
1995-12-08 |
2001-10-23 |
Hybridon, Inc. |
Modified VEGF oligonucleotides for treatment of skin disorders
|
US5731294A
(en)
*
|
1993-07-27 |
1998-03-24 |
Hybridon, Inc. |
Inhibition of neovasularization using VEGF-specific oligonucleotides
|
WO1995006131A1
(en)
*
|
1993-08-23 |
1995-03-02 |
Monash University |
A method for the assay, prophylaxis and/or treatment of human disease conditions
|
AUPM379394A0
(en)
*
|
1994-02-10 |
1994-03-03 |
Ludwig Institute For Cancer Research |
Immunointeractive molecules - i
|
US5861499A
(en)
|
1994-02-10 |
1999-01-19 |
Imclone Systems Incorporated |
Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
|
US5840301A
(en)
*
|
1994-02-10 |
1998-11-24 |
Imclone Systems Incorporated |
Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
|
US6811779B2
(en)
|
1994-02-10 |
2004-11-02 |
Imclone Systems Incorporated |
Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
|
US6448077B1
(en)
*
|
1994-02-10 |
2002-09-10 |
Imclone Systems, Inc. |
Chimeric and humanized monoclonal antibodies specific to VEGF receptors
|
GB9410533D0
(en)
*
|
1994-05-26 |
1994-07-13 |
Lynxvale Ltd |
In situ hybridisation and immuno-Chemical localisation of a growth factor
|
ATE326484T1
(de)
*
|
1994-06-09 |
2006-06-15 |
Licensing Oy |
Monoklonaler antikörper gegen flt4-rezeptor- tyrosinkinase und dessen verwendung zur diagnose und therapie
|
WO1996006641A1
(en)
*
|
1994-08-29 |
1996-03-07 |
Prizm Pharmaceuticals, Inc. |
Conjugates of vascular endothelial growth factor with targeted agents
|
EP1353952B1
(de)
|
1994-11-14 |
2007-04-11 |
Ludwig Institute For Cancer Research |
Flt4 (vegfr-3) als ein ziel für krebs darstellung und anti-krebs-behandlung
|
EP0854185A3
(de)
*
|
1994-12-23 |
1998-10-21 |
Ludwig Institute For Cancer Research |
Rezeptor-Proteine zu Bestimmungszwecke und Liganden
|
IL117645A
(en)
*
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
US6316635B1
(en)
|
1995-06-07 |
2001-11-13 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
US5650415A
(en)
*
|
1995-06-07 |
1997-07-22 |
Sugen, Inc. |
Quinoline compounds
|
US6906093B2
(en)
|
1995-06-07 |
2005-06-14 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
DE69618587T2
(de)
*
|
1995-06-07 |
2002-08-29 |
Sugen, Inc. |
Chinazoline und pharmazeutische zusammensetzungen
|
US5880141A
(en)
*
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
US5710173A
(en)
*
|
1995-06-07 |
1998-01-20 |
Sugen, Inc. |
Thienyl compounds for inhibition of cell proliferative disorders
|
US5773459A
(en)
*
|
1995-06-07 |
1998-06-30 |
Sugen, Inc. |
Urea- and thiourea-type compounds
|
WO1996040629A1
(en)
*
|
1995-06-07 |
1996-12-19 |
Sugen, Inc. |
Tyrphostin-like compounds for the treatment of cell proliferative disorders or cell differentiation disorders
|
US6147106A
(en)
|
1997-08-20 |
2000-11-14 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
WO1997000957A1
(en)
*
|
1995-06-23 |
1997-01-09 |
President And Fellows Of Harvard College |
Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
|
US5888765A
(en)
*
|
1995-06-23 |
1999-03-30 |
President And Fellows Of Harvard College |
Endothelial-cell specific promoter
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US5730977A
(en)
*
|
1995-08-21 |
1998-03-24 |
Mitsui Toatsu Chemicals, Inc. |
Anti-VEGF human monoclonal antibody
|
DE69628652T3
(de)
|
1995-09-08 |
2012-05-03 |
Genentech, Inc. |
Vegf-verwandtes protein
|
JPH09154588A
(ja)
|
1995-10-07 |
1997-06-17 |
Toagosei Co Ltd |
Vegf結合性ポリペプチド
|
US5942385A
(en)
*
|
1996-03-21 |
1999-08-24 |
Sugen, Inc. |
Method for molecular diagnosis of tumor angiogenesis and metastasis
|
US6030955A
(en)
*
|
1996-03-21 |
2000-02-29 |
The Trustees Of Columbia University In The City Of New York And Imclone Systems, Inc. |
Methods of affecting intracellular phosphorylation of tyrosine using phosphorothioate oligonucleotides, and antiangiogenic and antiproliferative uses thereof
|
US6696448B2
(en)
|
1996-06-05 |
2004-02-24 |
Sugen, Inc. |
3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
|
DE69733204T3
(de)
|
1996-07-15 |
2012-03-08 |
Chugai Seiyaku K.K. |
Neuartige vegf-ähnliche faktoren
|
US6426335B1
(en)
|
1997-10-17 |
2002-07-30 |
Gilead Sciences, Inc. |
Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
|
US6051698A
(en)
*
|
1997-06-06 |
2000-04-18 |
Janjic; Nebojsa |
Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
|
WO1998028006A1
(en)
*
|
1996-12-23 |
1998-07-02 |
Cambridge University Technical Services Limited |
Diagnosis and treatment of pathological pregnancies
|
JP3837748B2
(ja)
|
1997-01-17 |
2006-10-25 |
東亞合成株式会社 |
Vegf結合性ポリペプチド
|
JP2002514201A
(ja)
|
1997-01-22 |
2002-05-14 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
凝固および腫瘍の処置のための組織因子の方法および組成物
|
US5981508A
(en)
*
|
1997-01-29 |
1999-11-09 |
Vanderbilt University |
Facilitation of repair of neural injury with CM101/GBS toxin
|
US6670337B1
(en)
|
1998-01-29 |
2003-12-30 |
Yeda Reaearch And Development Co., Ltd. |
Facilitation of wound healing with CM101/GBS toxin
|
US5858991A
(en)
*
|
1997-01-29 |
1999-01-12 |
Vanderbilt University |
Facilitation of wound healing with CM101/GBS toxin
|
US6028060A
(en)
|
1997-01-29 |
2000-02-22 |
Vanderbilt University |
Treatment of chronic inflammatory diseases with CM101/GBS toxin
|
US7122636B1
(en)
*
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
US7365166B2
(en)
|
1997-04-07 |
2008-04-29 |
Genentech, Inc. |
Anti-VEGF antibodies
|
PT1325932E
(pt)
|
1997-04-07 |
2005-06-30 |
Genentech Inc |
Anticorpos anti-vegf
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
WO1998045332A2
(en)
*
|
1997-04-07 |
1998-10-15 |
Genentech, Inc. |
Humanized antibodies and methods for forming humanized antibodies
|
US6884879B1
(en)
*
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US6316429B1
(en)
|
1997-05-07 |
2001-11-13 |
Sugen, Inc. |
Bicyclic protein kinase inhibitors
|
US6486185B1
(en)
|
1997-05-07 |
2002-11-26 |
Sugen, Inc. |
3-heteroarylidene-2-indolinone protein kinase inhibitors
|
AU7345798A
(en)
*
|
1997-05-12 |
1998-12-08 |
Kennedy Institute Of Rheumatology, The |
Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy
|
US6987113B2
(en)
|
1997-06-11 |
2006-01-17 |
Sugen, Inc. |
Tyrosine kinase inhibitors
|
US6313158B1
(en)
|
1997-06-20 |
2001-11-06 |
Sugen, Inc. |
Bioavailability of 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors
|
US6114371A
(en)
*
|
1997-06-20 |
2000-09-05 |
Sugen, Inc. |
3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
|
US6051593A
(en)
|
1997-06-20 |
2000-04-18 |
Sugen, Inc. |
3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
|
US6130238A
(en)
*
|
1997-06-20 |
2000-10-10 |
Sugen, Inc. |
3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
|
US6329375B1
(en)
|
1997-08-05 |
2001-12-11 |
Sugen, Inc. |
Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
|
JPH1180024A
(ja)
*
|
1997-09-12 |
1999-03-23 |
Toagosei Co Ltd |
角膜血管新生阻害剤
|
US6133305A
(en)
|
1997-09-26 |
2000-10-17 |
Sugen, Inc. |
3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
|
DE19744531A1
(de)
*
|
1997-10-09 |
1999-05-27 |
Klaus Dr Rer Nat Bosslet |
Bindemoleküle gegen Rezeptor-Ligand-Komplexe
|
US6225346B1
(en)
|
1997-10-24 |
2001-05-01 |
Sugen, Inc. |
Tyrphostin like compounds
|
US6531502B1
(en)
|
1998-01-21 |
2003-03-11 |
Sugen, Inc. |
3-Methylidenyl-2-indolinone modulators of protein kinase
|
DK1064382T3
(da)
*
|
1998-03-17 |
2008-12-08 |
Genentech Inc |
Homologe polypeptider til VEGF og BMP1
|
EP2311495B1
(de)
|
1998-03-24 |
2014-09-24 |
Chugai Seiyaku Kabushiki Kaisha |
Inhibitoren der Vaskularisierung
|
US6514981B1
(en)
|
1998-04-02 |
2003-02-04 |
Sugen, Inc. |
Methods of modulating tyrosine protein kinase function with indolinone compounds
|
US6887674B1
(en)
|
1998-04-13 |
2005-05-03 |
California Institute Of Technology |
Artery- and vein-specific proteins and uses therefor
|
US6864227B1
(en)
|
1998-04-13 |
2005-03-08 |
California Institute Of Technology |
Artery-and vein-specific proteins and uses therefor
|
EP2020408B1
(de)
|
1998-05-29 |
2013-06-26 |
Sugen, Inc. |
Pyrrol-substituiertes 2-Indolinon als Proteinkinase-Hemmer
|
JP2002523455A
(ja)
|
1998-08-31 |
2002-07-30 |
スージェン・インコーポレーテッド |
蛋白質キナーゼ活性の調節剤としての幾何学的に制限された2−インドリノン誘導体
|
DE69928411D1
(de)
|
1998-09-08 |
2005-12-22 |
Agouron Pharma |
Modifikationen des vegf-rezeptor-2 proteins und verfahren zu seiner verwendung
|
US6680335B2
(en)
|
1998-09-28 |
2004-01-20 |
Sugen, Inc. |
Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
|
AU1103900A
(en)
|
1998-10-07 |
2000-04-26 |
Stryker Corporation |
Modified tgf-beta superfamily proteins
|
AU774266B2
(en)
|
1998-10-09 |
2004-06-24 |
Vegenics Limited |
Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
|
CA2355976C
(en)
|
1998-12-22 |
2012-07-17 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists and uses thereof
|
US6689806B1
(en)
|
1999-03-24 |
2004-02-10 |
Sugen, Inc. |
Indolinone compounds as kinase inhibitors
|
JP4926320B2
(ja)
|
1999-04-28 |
2012-05-09 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
Vegfの選択的阻害による癌処置のための組成物および方法
|
US6703020B1
(en)
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
IT1306704B1
(it)
*
|
1999-05-26 |
2001-10-02 |
Sirs Societa Italiana Per La R |
Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
|
ATE410685T1
(de)
*
|
1999-06-17 |
2008-10-15 |
Kyowa Hakko Kogyo Kk |
Diagnostikum und heilmittel für krankheiten unter teilnahme von makrozyten/makrophagen
|
US6921763B2
(en)
|
1999-09-17 |
2005-07-26 |
Abbott Laboratories |
Pyrazolopyrimidines as therapeutic agents
|
US6878733B1
(en)
|
1999-11-24 |
2005-04-12 |
Sugen, Inc. |
Formulations for pharmaceutical agents ionizable as free acids or free bases
|
DK1255536T3
(da)
|
1999-12-22 |
2006-10-30 |
Sugen Inc |
Indolinonderivater til modulation af c-kit-tyrosinproteinkinase
|
KR20020084116A
(ko)
|
2000-02-07 |
2002-11-04 |
애보트 게엠베하 운트 콤파니 카게 |
2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도
|
EP2286843A3
(de)
|
2000-06-02 |
2011-08-03 |
Bracco Suisse SA |
Arzneimitteln zur Zielgerichtung von Endothelzellen
|
US8263739B2
(en)
|
2000-06-02 |
2012-09-11 |
Bracco Suisse Sa |
Compounds for targeting endothelial cells, compositions containing the same and methods for their use
|
US6726918B1
(en)
|
2000-07-05 |
2004-04-27 |
Oculex Pharmaceuticals, Inc. |
Methods for treating inflammation-mediated conditions of the eye
|
US7175844B2
(en)
|
2000-07-18 |
2007-02-13 |
Joslin Diabetes Center, Inc. |
Methods of modulating fibrosis
|
ES2250504T3
(es)
|
2000-11-29 |
2006-04-16 |
Allergan Inc. |
Prevencion del rechazo de injerto en el ojo.
|
PT2762140T
(pt)
|
2001-02-19 |
2017-07-04 |
Novartis Ag |
Resumo
|
MXPA03008560A
(es)
|
2001-03-22 |
2004-06-30 |
Abbot Gmbh & Co Kg |
Pirazolopirimidinas como agentes terapeuticos.
|
MXPA03010401A
(es)
|
2001-05-16 |
2004-03-09 |
Novartis Ag |
Combinacion que comprende n-[5-[4- (4-metil- piperazino-metil) -benzoilamido] -2-metilfenil] -4-(3-piridil)-2 -pirimidin-amina, y un agente quimioterapeutico.
|
DE60233509D1
(de)
|
2001-06-20 |
2009-10-08 |
Fibron Ltd |
Fgfr3 blockierende antikörper, verfahren zum screening darauf und verwendungen davon
|
TWI315982B
(en)
|
2001-07-19 |
2009-10-21 |
Novartis Ag |
Combinations comprising epothilones and pharmaceutical uses thereof
|
EP1430048A1
(de)
|
2001-09-27 |
2004-06-23 |
Allergan, Inc. |
3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-one als kinase inhibitoren
|
US6559173B1
(en)
|
2001-09-27 |
2003-05-06 |
Allergan, Inc. |
3-(heteroarylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7211240B2
(en)
|
2002-03-01 |
2007-05-01 |
Bracco International B.V. |
Multivalent constructs for therapeutic and diagnostic applications
|
US7985402B2
(en)
|
2002-03-01 |
2011-07-26 |
Bracco Suisse Sa |
Targeting vector-phospholipid conjugates
|
US8623822B2
(en)
|
2002-03-01 |
2014-01-07 |
Bracco Suisse Sa |
KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
|
CA2513044A1
(en)
|
2002-03-01 |
2004-08-05 |
Dyax Corp. |
Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
|
US7261876B2
(en)
|
2002-03-01 |
2007-08-28 |
Bracco International Bv |
Multivalent constructs for therapeutic and diagnostic applications
|
US7666979B2
(en)
|
2002-03-01 |
2010-02-23 |
Bracco International B.V. |
Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
|
US7794693B2
(en)
|
2002-03-01 |
2010-09-14 |
Bracco International B.V. |
Targeting vector-phospholipid conjugates
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
US6541504B1
(en)
|
2002-04-03 |
2003-04-01 |
Allergan Sales, Llc |
(3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
|
DE60324416D1
(de)
|
2002-05-16 |
2008-12-11 |
Novartis Ag |
Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
ATE514717T1
(de)
|
2002-07-18 |
2011-07-15 |
Merus B V |
Rekombinante produktion von antikörpermischungen
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
AU2003297282A1
(en)
|
2002-11-14 |
2004-06-15 |
Cornell Research Foundation, Inc. |
Protection of cardiac myocardium
|
US6747025B1
(en)
|
2002-11-27 |
2004-06-08 |
Allergan, Inc. |
Kinase inhibitors for the treatment of disease
|
US6699863B1
(en)
|
2002-11-27 |
2004-03-02 |
Allergan, Inc. |
Kinase inhibitors for the treatment of disease
|
CU23204A1
(es)
*
|
2002-12-27 |
2007-05-18 |
Ct Ingenieria Genetica Biotech |
Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias
|
US20050048099A1
(en)
|
2003-01-09 |
2005-03-03 |
Allergan, Inc. |
Ocular implant made by a double extrusion process
|
RS53118B
(en)
|
2003-02-26 |
2014-06-30 |
Sugen Inc. |
AMINOHETEROARYL UNITS AS PROTEIN KINASE INHIBITORS
|
ES2557286T3
(es)
|
2003-03-03 |
2016-01-25 |
Dyax Corp. |
Usos de péptidos que se unen específicamente al receptor del HGF (cMet)
|
US7381410B2
(en)
|
2003-03-12 |
2008-06-03 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
JP2006521111A
(ja)
|
2003-03-12 |
2006-09-21 |
バスジーン セラピューティクス, インコーポレイテッド |
血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用
|
SI1615646T2
(sl)
|
2003-04-08 |
2022-11-30 |
Progenics Pharmaceuticals, Inc. |
Farmacevtske formulacije vsebujoče metilnatrekson
|
US7417065B2
(en)
|
2003-05-19 |
2008-08-26 |
Irm Llc |
Immunosuppressant compounds and compositions
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
WO2004106375A1
(en)
|
2003-05-30 |
2004-12-09 |
Merus Biopharmaceuticals B.V. I.O. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
KR20180014881A
(ko)
|
2003-05-30 |
2018-02-09 |
제넨테크, 인크. |
항-vegf 항체를 사용한 치료
|
EP1638600A4
(de)
|
2003-06-09 |
2008-06-11 |
Samuel Waksal |
Verfahren zur hemmung von rezeptor-tyrosin-kinasen mit einem extrazellulären antagonisten und einem intrazellulären antagonisten
|
CA2534509A1
(en)
|
2003-08-06 |
2005-02-24 |
Sugen, Inc. |
Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein kinase inhibitors
|
GB0320238D0
(en)
*
|
2003-08-29 |
2003-10-01 |
Medical Res Council |
Treatment of disease
|
WO2005046602A2
(en)
*
|
2003-11-10 |
2005-05-26 |
Greenville Hospital System |
Vegf receptor antagonists
|
KR20070034465A
(ko)
|
2004-03-12 |
2007-03-28 |
바스진 테라퓨틱스, 인크. |
혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물
|
AU2005224081B2
(en)
|
2004-03-12 |
2011-06-30 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
US8685435B2
(en)
|
2004-04-30 |
2014-04-01 |
Allergan, Inc. |
Extended release biodegradable ocular implants
|
US20050244469A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Extended therapeutic effect ocular implant treatments
|
JP2008500830A
(ja)
|
2004-06-01 |
2008-01-17 |
ドマンティス リミテッド |
増加した血清半減期を有する二重特異性融合抗体
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
US8604185B2
(en)
|
2004-07-20 |
2013-12-10 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
EP2361931B1
(de)
|
2004-07-20 |
2017-12-06 |
Genentech, Inc. |
Angiopoietin-like 4 Protein Hemmer Kombinationen und deren Verwendung
|
EP1804835B9
(de)
|
2004-09-13 |
2010-09-29 |
Genzyme Corporation |
Multimere konstrukte
|
CA2581423A1
(en)
|
2004-09-23 |
2006-03-30 |
Vasgene Therapeutics, Inc. |
Polipeptide compounds for inhibiting angiogenesis and tumor growth
|
EP2319492A3
(de)
|
2004-10-21 |
2011-08-10 |
Genentech, Inc. |
Verfahren zur Behandlung von intraokularen neovaskulären Erkrankungen
|
SI1819358T1
(sl)
|
2004-11-18 |
2014-10-30 |
Imclone Llc |
Protitelesa proti receptorju 1 za vaskularni endotelijski rastni dejavnik (vegfr-1)
|
US20080161251A1
(en)
|
2005-01-21 |
2008-07-03 |
Astex Therapeutics Limited |
Pharmaceutical Compounds
|
US8524731B2
(en)
|
2005-03-07 |
2013-09-03 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
US9662325B2
(en)
|
2005-03-07 |
2017-05-30 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
CN104248763A
(zh)
|
2005-03-07 |
2014-12-31 |
芝加哥大学 |
阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
|
US8518962B2
(en)
|
2005-03-07 |
2013-08-27 |
The University Of Chicago |
Use of opioid antagonists
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
AR057325A1
(es)
|
2005-05-25 |
2007-11-28 |
Progenics Pharm Inc |
Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
|
AR057035A1
(es)
|
2005-05-25 |
2007-11-14 |
Progenics Pharm Inc |
SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
|
EP1996550A2
(de)
|
2005-09-27 |
2008-12-03 |
Novartis AG |
Carxoxyamin-zusammensetzungen und ihre verwendung bei der behandlung von hdac-abhängigen krankheiten
|
CA2933875C
(en)
|
2005-11-21 |
2018-06-26 |
Novartis Ag |
40-o-(2-hydroxyethyl)-rapamycin for use as a sole drug substance in the treatment of carcinoid tumors arising from the foregut, midgut, or hindgut
|
DK1973950T3
(en)
|
2006-01-05 |
2014-12-15 |
Genentech Inc |
ANTI-EphB4 ANTIBODIES AND METHODS FOR USING SAME
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
US8367664B2
(en)
|
2006-01-24 |
2013-02-05 |
Allergan, Inc. |
Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
|
US7977351B2
(en)
|
2006-03-22 |
2011-07-12 |
Allergan, Inc. |
Heteroaryl dihydroindolones as kinase inhibitors
|
TW200812615A
(en)
|
2006-03-22 |
2008-03-16 |
Hoffmann La Roche |
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
|
EP2591775A1
(de)
|
2006-04-05 |
2013-05-15 |
Novartis AG |
Kombinationen mit MTOR-Hemmern zur Krebsbehandlung
|
AR060358A1
(es)
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
AR060635A1
(es)
|
2006-04-27 |
2008-07-02 |
Banyu Pharma Co Ltd |
Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
|
AU2007247112B2
(en)
|
2006-05-09 |
2010-08-26 |
Novartis Ag |
Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
|
WO2008060705A2
(en)
|
2006-06-06 |
2008-05-22 |
Genentech, Inc. |
Anti-dll4 antibodies and methods using same
|
GB0612721D0
(en)
|
2006-06-27 |
2006-08-09 |
Novartis Ag |
Organic compounds
|
NZ574580A
(en)
|
2006-08-21 |
2011-12-22 |
Hoffmann La Roche |
Her2 tumor therapy with an anti-vegf antibody
|
JP2008081492A
(ja)
|
2006-08-31 |
2008-04-10 |
Banyu Pharmaceut Co Ltd |
オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
|
ATE502943T1
(de)
|
2006-09-29 |
2011-04-15 |
Novartis Ag |
Pyrazolopyrimidine als pi3k-lipidkinasehemmer
|
WO2008044045A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
EP2073803B1
(de)
|
2006-10-12 |
2018-09-19 |
Astex Therapeutics Limited |
Pharmazeutische kombinationen
|
US8558002B2
(en)
|
2006-11-16 |
2013-10-15 |
Allergan, Inc. |
Sulfoximines as kinase inhibitors
|
WO2008061236A2
(en)
|
2006-11-16 |
2008-05-22 |
Allergan, Inc. |
Sulfoximines as kinase inhibitors
|
JP2010513566A
(ja)
|
2006-12-19 |
2010-04-30 |
ジェネンテック, インコーポレイテッド |
アジュバント療法およびネオアジュバント療法のためのvegf特異的アンタゴニストと初期ステージ腫瘍の治療
|
US7977336B2
(en)
|
2006-12-28 |
2011-07-12 |
Banyu Pharmaceutical Co. Ltd |
Aminopyrimidine derivatives as PLK1 inhibitors
|
MX2009008584A
(es)
|
2007-02-15 |
2009-08-18 |
Novartis Ag |
Combinacion de lbh589 con otros agentes terapeuticos para el tratamiento de cancer.
|
AR065877A1
(es)
|
2007-03-29 |
2009-07-08 |
Progenics Pharm Inc |
Antagonoistas del receptor opioide periferico y usos de los mismos
|
MX2009010550A
(es)
|
2007-03-29 |
2009-12-14 |
Progenics Pharm Inc |
Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
|
PT2139890E
(pt)
|
2007-03-29 |
2014-09-03 |
Wyeth Llc |
Antagonistas do receptor opióide periférico e respectivas utilizações
|
ES2541051T3
(es)
|
2007-05-17 |
2015-07-15 |
Genentech, Inc. |
Estructuras cristalinas de fragmentos de neuropilina y complejos neuropilina-anticuerpo
|
US8231892B2
(en)
|
2007-05-24 |
2012-07-31 |
Allergan, Inc. |
Biodegradable drug delivery system
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
KR100883430B1
(ko)
|
2007-06-13 |
2009-02-12 |
한국생명공학연구원 |
혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
|
JP5749009B2
(ja)
|
2007-08-13 |
2015-07-15 |
バスジーン セラピューティクス,インコーポレイテッドVasgenetherapeutics,Inc. |
EphB4に結合するヒト化抗体を利用する癌治療剤
|
AU2008315048A1
(en)
|
2007-10-23 |
2009-04-30 |
Msd K.K. |
Pyridone-substituted-dihydropyrazolopyrimidinone derivative
|
PE20090983A1
(es)
|
2007-11-09 |
2009-08-13 |
Genentech Inc |
Composiciones y metodos de uso de la quinasa-1 similar al receptor de la activina
|
CA2705537A1
(en)
|
2007-11-12 |
2009-05-22 |
Bipar Sciences, Inc. |
Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
|
TWI580694B
(zh)
|
2007-11-30 |
2017-05-01 |
建南德克公司 |
抗-vegf抗體
|
PE20091523A1
(es)
|
2007-12-20 |
2009-10-29 |
Novartis Ag |
Derivados de tiazol como inhibidores de la enzima fosfatidilinositol 3-cinasa (pi3k)
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
EP2240489A1
(de)
|
2008-02-06 |
2010-10-20 |
Progenics Pharmaceuticals, Inc. |
HERSTELLUNG UND VERWENDUNG VON (R), (R)-2,2ýBIS-METHYLNALTREXON
|
WO2009117669A2
(en)
|
2008-03-21 |
2009-09-24 |
The University Of Chicago |
Treatment with opioid antagonists and mtor inhibitors
|
EP2628726A1
(de)
|
2008-03-26 |
2013-08-21 |
Novartis AG |
Auf Hydroxamat basierende Hemmer von Deacetylasen B
|
JP5425180B2
(ja)
|
2008-03-27 |
2014-02-26 |
ザイモジェネティクス, インコーポレイテッド |
PDGFRβおよびVEGF−Aを阻害するための組成物および方法
|
EP3216803B1
(de)
|
2008-06-25 |
2020-03-11 |
Novartis Ag |
Stabile und lösliche, vegf-inhibierende antikörper
|
JP5606438B2
(ja)
|
2008-07-23 |
2014-10-15 |
エフ.ホフマン−ラ ロシュ アーゲー |
抗血管新生療法を受容可能な被験体の同定
|
CA2676881C
(en)
|
2008-09-30 |
2017-04-25 |
Wyeth |
Peripheral opioid receptor antagonists and uses thereof
|
US8268314B2
(en)
|
2008-10-08 |
2012-09-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-VEGF/anti-ANG-2 antibodies
|
TWI572357B
(zh)
|
2008-10-14 |
2017-03-01 |
建南德克公司 |
免疫球蛋白變異體及其用途
|
WO2010043050A1
(en)
|
2008-10-16 |
2010-04-22 |
Celator Pharmaceuticals Corporation |
Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
|
PL2361085T5
(pl)
|
2008-11-22 |
2018-12-31 |
F.Hoffmann-La Roche Ag |
Zastosowanie przeciwciała anty-vegf w połączeniu z chemioterapią w leczeniu raka sutka
|
KR20110112352A
(ko)
|
2008-12-18 |
2011-10-12 |
노파르티스 아게 |
1-(4-{l-[(e)-4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노]-에틸}-2-에틸-벤질)-아제티딘-3-카르복실산의 신규한 다형체 형태
|
US20120115840A1
(en)
|
2008-12-18 |
2012-05-10 |
Lech Ciszewski |
Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid
|
EP2379499B1
(de)
|
2008-12-18 |
2014-04-09 |
Novartis AG |
Hydrochlorid Salz der 1-(4-(1-((E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl)-2-ethyl-benzyl)-azetidin-3-carbonsäure
|
KR101596539B1
(ko)
|
2008-12-23 |
2016-02-22 |
제넨테크, 인크. |
암 환자에서의 진단 목적용 방법 및 조성물
|
JP2012516345A
(ja)
|
2009-01-29 |
2012-07-19 |
ノバルティス アーゲー |
星細胞腫治療用置換ベンゾイミダゾール
|
WO2010091234A2
(en)
|
2009-02-06 |
2010-08-12 |
The General Hospital Corporation |
Methods of treating vascular lesions
|
CA2750716A1
(en)
|
2009-02-25 |
2010-09-02 |
Msd K.K. |
Pyrimidopyrimidoindazole derivative
|
EP2403339B1
(de)
|
2009-03-06 |
2017-01-18 |
Merck Sharp & Dohme Corp. |
Tumorkombinationstherapie mit einem akt-hemmer und anderen antumormitteln
|
EP2414391B1
(de)
|
2009-04-02 |
2018-11-28 |
Roche Glycart AG |
Multispezifische antikörper, umfassend vollständige antikörper und einzelketten-fab-fragmente
|
PL2417156T3
(pl)
|
2009-04-07 |
2015-07-31 |
Roche Glycart Ag |
Trójwartościowe, bispecyficzne przeciwciała
|
CA2760246A1
(en)
|
2009-05-08 |
2010-11-11 |
Weilan Ye |
Humanized anti-egfl7 antibodies and methods using same
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
UA105794C2
(uk)
|
2009-06-26 |
2014-06-25 |
Новартіс Аг |
1,3-ДИЗАМІЩЕНІ ПОХІДНІ ІМІДАЗОЛІДИН-2-ОНУ ЯК ІНГІБІТОРИ Cyp17
|
EP2450055B1
(de)
|
2009-06-30 |
2018-01-03 |
Obshestvo S OgranichennoyOtvetstvennostiu"OncoMax" |
Verfahren zur unterdrückung des nierentumorwachstums mittels blockierung des fibroblastenwachstumsfaktor-rezektors
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
US20110076271A1
(en)
|
2009-07-13 |
2011-03-31 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
AR077595A1
(es)
|
2009-07-27 |
2011-09-07 |
Genentech Inc |
Tratamientos de combinacion
|
MX2012001306A
(es)
|
2009-07-31 |
2012-02-28 |
Genentech Inc |
Inhibicion de matastasis de tumor.
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
AU2010283806A1
(en)
|
2009-08-12 |
2012-03-01 |
Novartis Ag |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
|
SG178419A1
(en)
|
2009-08-15 |
2012-04-27 |
Genentech Inc |
Anti-angiogenesis therapy for the treatment of previously treated breast cancer
|
ES2709108T3
(es)
|
2009-08-17 |
2019-04-15 |
Intellikine Llc |
Compuestos heterocíclicos y usos de los mismos
|
AU2010284972A1
(en)
|
2009-08-20 |
2012-03-08 |
Novartis Ag |
Heterocyclic oxime compounds
|
EA201200321A1
(ru)
|
2009-08-26 |
2012-09-28 |
Новартис Аг |
Тетразамещенные гетероарильные соединения и их применение в качестве модуляторов mdm2 и/или mdm4
|
WO2011028642A1
(en)
|
2009-09-04 |
2011-03-10 |
University Of Louisville Research Foundation, Inc. |
Genetic determinants of prostate cancer risk
|
IN2012DN02139A
(de)
|
2009-09-10 |
2015-08-07 |
Novartis Ag |
|
JP2013504595A
(ja)
|
2009-09-11 |
2013-02-07 |
ジェネンテック, インコーポレイテッド |
抗癌剤に対する応答の可能性が増加した患者を同定するための方法
|
RU2573915C2
(ru)
|
2009-09-16 |
2016-01-27 |
Дженентек, Инк. |
Содержащие суперспираль и/или привязку белковые комплексы и их применение
|
ES2530732T3
(es)
|
2009-09-17 |
2015-03-05 |
Hoffmann La Roche |
Procedimientos de diagnóstico para el cáncer de pulmón
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
MX2012005293A
(es)
|
2009-11-04 |
2012-06-19 |
Novartis Ag |
Derivados de sulfonamida heterociclicos utiles como inhibidores de mek.
|
WO2011064211A1
(en)
|
2009-11-25 |
2011-06-03 |
Novartis Ag |
Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
|
JP5456908B2
(ja)
|
2009-12-08 |
2014-04-02 |
ノバルティス アーゲー |
ヘテロ環式スルホンアミド誘導体
|
US8486397B2
(en)
|
2009-12-11 |
2013-07-16 |
Genentech, Inc. |
Anti-VEGF-C antibodies and methods using same
|
CN102770158B
(zh)
|
2009-12-21 |
2016-10-19 |
霍夫曼-拉罗奇有限公司 |
抗体配制剂
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
AU2010336485B2
(en)
|
2009-12-23 |
2015-03-26 |
Genentech, Inc. |
Anti-Bv8 antibodies and uses thereof
|
EP2539367A2
(de)
|
2010-02-23 |
2013-01-02 |
F. Hoffmann-La Roche AG |
Anti-angiogenese-therapie für die behandlung von ovarialkarzinom
|
TWI426920B
(zh)
|
2010-03-26 |
2014-02-21 |
Hoffmann La Roche |
雙專一性、雙價抗-vegf/抗-ang-2抗體
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
CN102947274A
(zh)
|
2010-06-17 |
2013-02-27 |
诺瓦提斯公司 |
联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
|
WO2011157793A1
(en)
|
2010-06-17 |
2011-12-22 |
Novartis Ag |
Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
EP2848940A1
(de)
|
2010-07-19 |
2015-03-18 |
F. Hoffmann-La Roche AG |
Verfahren zur Identifizierung eines Patienten mit erhöhter Wahrscheinlichkeit des Ansprechens auf eine Antitumortherapie
|
EP2596359A1
(de)
|
2010-07-19 |
2013-05-29 |
F.Hoffmann-La Roche Ag |
Verfahren zur identifizierung eines patienten mit erhöhter wahrscheinlichkeit des ansprechens auf eine antitumortherapie
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
SI2601214T1
(en)
|
2010-08-06 |
2018-03-30 |
Genzyme Corporation |
VEGF antagonist compositions and their use
|
AR082693A1
(es)
|
2010-08-17 |
2012-12-26 |
Roche Glycart Ag |
Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
|
BR112013001847A2
(pt)
|
2010-08-24 |
2016-05-31 |
Hoffmann La Roche |
anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica
|
JP2013537210A
(ja)
|
2010-09-16 |
2013-09-30 |
ノバルティス アーゲー |
17α−ヒドロキシラーゼ/C17,20−リアーゼ阻害剤
|
EP2447301A1
(de)
|
2010-10-29 |
2012-05-02 |
Rhein Chemie Rheinau GmbH |
Verfahren zur Herstellung von Gusspolyamiden
|
SG190788A1
(en)
|
2010-11-15 |
2013-07-31 |
Five Prime Therapeutics Inc |
Fgfr1 extracellular domain combination therapies
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
UY33883A
(es)
|
2011-01-31 |
2012-08-31 |
Novartis Ag |
Novedosos derivados heterocíclicos
|
EP2673277A1
(de)
|
2011-02-10 |
2013-12-18 |
Novartis AG |
[1, 2, 4] triazolo [4, 3]pyridazinverbindungen als inhibitoren dec-met-tyrosinkinase
|
US9127000B2
(en)
|
2011-02-23 |
2015-09-08 |
Intellikine, LLC. |
Heterocyclic compounds and uses thereof
|
EP2681239B8
(de)
|
2011-02-28 |
2015-09-09 |
F. Hoffmann-La Roche AG |
Antigenbindende proteine
|
MX342034B
(es)
|
2011-02-28 |
2016-09-12 |
Hoffmann La Roche |
Proteinas monovalentes que se unen a antigenos.
|
CN103492390A
(zh)
|
2011-03-08 |
2014-01-01 |
诺瓦提斯公司 |
氟苯基双环杂芳基化合物
|
PT2691417T
(pt)
|
2011-03-29 |
2018-10-31 |
Roche Glycart Ag |
Variantes de fc de anticorpos
|
EP2694072B1
(de)
|
2011-04-01 |
2017-11-29 |
Genentech, Inc. |
Kombination von akt-hemmer-verbindung und abirateron zur verwendung in therapeutischen verfahren
|
CN108178789B
(zh)
|
2011-04-20 |
2021-11-02 |
阿塞勒隆制药公司 |
内皮糖蛋白多肽及其用途
|
JP6002210B2
(ja)
|
2011-04-28 |
2016-10-05 |
ノバルティス アーゲー |
17α−ヒドロキシラーゼ/C17,20−リアーゼ阻害剤
|
CA2834776A1
(en)
|
2011-05-03 |
2012-11-08 |
Genentech, Inc. |
Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
|
CA2838029A1
(en)
|
2011-06-09 |
2012-12-13 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
WO2012175487A1
(en)
|
2011-06-20 |
2012-12-27 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
US8859535B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
WO2013025944A1
(en)
|
2011-08-17 |
2013-02-21 |
Genentech, Inc. |
Inhibition of angiogenesis in refractory tumors
|
BR112014006223A8
(pt)
|
2011-09-15 |
2018-01-09 |
Novartis Ag |
3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação
|
WO2013061305A1
(en)
|
2011-10-28 |
2013-05-02 |
Novartis Ag |
Novel purine derivatives and their use in the treatment of disease
|
EP2785717B1
(de)
|
2011-11-29 |
2016-01-13 |
Novartis AG |
Pyrazolopyrrolidinverbindungen
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
WO2013096060A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
MX2014007729A
(es)
|
2011-12-23 |
2015-01-12 |
Novartis Ag |
Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
|
KR20140107578A
(ko)
|
2011-12-23 |
2014-09-04 |
노파르티스 아게 |
Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
|
MX2014007730A
(es)
|
2011-12-23 |
2015-01-12 |
Novartis Ag |
Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
|
CN104136429A
(zh)
|
2011-12-23 |
2014-11-05 |
诺华股份有限公司 |
用于抑制bcl2与结合配偶体相互作用的化合物
|
US8815926B2
(en)
|
2012-01-26 |
2014-08-26 |
Novartis Ag |
Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
|
EP2812357B1
(de)
|
2012-02-10 |
2020-11-04 |
F.Hoffmann-La Roche Ag |
Einzelketten-antikörper und andere heteromultimere
|
PE20141909A1
(es)
|
2012-03-13 |
2014-11-29 |
Hoffmann La Roche |
Terapia combinada para el tratamiento del cancer de ovario
|
CN104245701A
(zh)
|
2012-04-03 |
2014-12-24 |
诺华有限公司 |
有酪氨酸激酶抑制剂的组合产品和其应用
|
PT2838917T
(pt)
|
2012-04-20 |
2019-09-12 |
Merus Nv |
Métodos e meios para a produção de moléculas similares a ig heterodiméricas
|
US10213432B2
(en)
|
2012-05-16 |
2019-02-26 |
Novartis Ag |
Dosage regimen for a PI-3 kinase inhibitor
|
EP2855483B1
(de)
|
2012-05-24 |
2017-10-25 |
Novartis AG |
Pyrrolopyrrolidinonverbindungen
|
CA2874144C
(en)
|
2012-05-31 |
2023-12-19 |
Genentech, Inc. |
Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
|
JP6203838B2
(ja)
|
2012-06-27 |
2017-09-27 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
少なくとも2つの異なる結合実体を含む、テーラーメイドの高度に選択的かつ多重特異的なターゲティング実体を選択および作製するための方法、ならびにその使用
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
ES2896493T3
(es)
|
2012-07-13 |
2022-02-24 |
Roche Glycart Ag |
Anticuerpos biespecíficos anti-VEGF/anti-ANG-2 y su uso en el tratamiento de enfermedades vasculares oculares
|
WO2014025813A1
(en)
|
2012-08-07 |
2014-02-13 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
AU2014205369B2
(en)
|
2013-01-11 |
2018-08-09 |
Massachusetts Eye And Ear Infirmary |
CYP450 lipid metabolites reduce inflammation and angiogenesis
|
EP2948453B1
(de)
|
2013-01-22 |
2017-08-02 |
Novartis AG |
Pyrazolo[3,4-d]pyrimidinonverbindungen als inhibitoren der p53/mdm2-interaktion
|
WO2014115077A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Substituted purinone compounds
|
EP3693381A1
(de)
|
2013-02-18 |
2020-08-12 |
Vegenics Pty Limited |
Ligandbindende moleküle und verwendungen davon
|
CA2906057A1
(en)
|
2013-03-13 |
2014-10-02 |
Genentech, Inc. |
Antibody formulations
|
EP2968340A4
(de)
|
2013-03-15 |
2016-08-10 |
Intellikine Llc |
Kombination von kinaseinhibitoren und verwendungen davon
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
WO2014190147A2
(en)
|
2013-05-23 |
2014-11-27 |
Five Prime Therapeutics, Inc. |
Methods of treating cancer
|
CN104341504B
(zh)
|
2013-08-06 |
2017-10-24 |
百奥泰生物科技(广州)有限公司 |
双特异性抗体
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
JP6422956B2
(ja)
|
2013-10-11 |
2018-11-14 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
多重特異性ドメイン交換共通可変軽鎖抗体
|
EA035481B1
(ru)
|
2013-10-25 |
2020-06-23 |
Акселерон Фарма, Инк. |
Эндоглиновые пептиды для лечения фиброзных заболеваний
|
ES2875878T3
(es)
|
2013-11-18 |
2021-11-11 |
Formycon Ag |
Composición farmacéutica de un anticuerpo anti-VEGF
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
JP2016539149A
(ja)
|
2013-12-06 |
2016-12-15 |
ノバルティス アーゲー |
アルファ−アイソフォーム選択的ホスファチジルイノシトール3−キナーゼ阻害剤の投薬レジメン
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
EP3104880B1
(de)
|
2014-02-14 |
2020-03-25 |
MacroGenics, Inc. |
Verbesserte verfahren zur behandlung von vaskularisierenden karzinomen
|
AU2015229103C9
(en)
|
2014-03-14 |
2020-11-26 |
Immutep S.A.S |
Antibody molecules to LAG-3 and uses thereof
|
MA39776A
(fr)
|
2014-03-24 |
2017-02-01 |
Hoffmann La Roche |
Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
|
MX2016012779A
(es)
|
2014-03-31 |
2017-04-27 |
Genentech Inc |
Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
|
EP3143044A1
(de)
|
2014-05-12 |
2017-03-22 |
Formycon AG |
Vorgefüllte spritze aus kunststoff mit einem vegf-antagonisten
|
EP3169801A1
(de)
|
2014-07-14 |
2017-05-24 |
F. Hoffmann-La Roche AG |
Diagnostische verfahren und zusammensetzungen zur behandlung von glioblastomen
|
MX2017001461A
(es)
|
2014-07-31 |
2017-05-11 |
Novartis Ag |
Terapia de combinacion.
|
WO2016025645A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
|
AU2015301753B2
(en)
|
2014-08-12 |
2021-04-08 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with IL-2 and integrin-binding-Fc-fusion protein
|
EP3925622A1
(de)
|
2014-09-13 |
2021-12-22 |
Novartis AG |
Kombinationstherapien
|
WO2016044334A1
(en)
|
2014-09-15 |
2016-03-24 |
Genentech, Inc. |
Antibody formulations
|
US20170209574A1
(en)
|
2014-10-03 |
2017-07-27 |
Novartis Ag |
Combination therapies
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
TWI716362B
(zh)
|
2014-10-14 |
2021-01-21 |
瑞士商諾華公司 |
針對pd-l1之抗體分子及其用途
|
EA201791029A1
(ru)
|
2014-11-10 |
2017-12-29 |
Дженентек, Инк. |
Антитела против интерлейкина-33 и их применение
|
ES2764111T3
(es)
|
2014-12-03 |
2020-06-02 |
Hoffmann La Roche |
Anticuerpos multiespecíficos
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
SG11201704707PA
(en)
|
2014-12-23 |
2017-07-28 |
Genentech Inc |
Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
|
CN107750164A
(zh)
|
2015-06-08 |
2018-03-02 |
豪夫迈·罗氏有限公司 |
使用抗ox40抗体和pd‑1轴结合拮抗剂治疗癌症的方法
|
US20180222982A1
(en)
|
2015-07-29 |
2018-08-09 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
LT3317301T
(lt)
|
2015-07-29 |
2021-07-26 |
Novartis Ag |
Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
|
EP3316902A1
(de)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Kombinationstherapien mit antikörpermolekülen gegen tim-3
|
CA3001362C
(en)
|
2015-10-30 |
2020-10-13 |
Genentech, Inc. |
Anti-htra1 antibodies and methods of use thereof
|
AU2016347881A1
(en)
|
2015-11-02 |
2018-05-10 |
Novartis Ag |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
JP2019500893A
(ja)
|
2015-11-03 |
2019-01-17 |
ヤンセン バイオテツク,インコーポレーテツド |
Pd−1及びtim−3に特異的に結合する抗体及びそれらの使用
|
US11654046B2
(en)
|
2015-11-18 |
2023-05-23 |
Sio2 Medical Products, Inc. |
Pharmaceutical package for ophthalmic formulations
|
MX2018006092A
(es)
|
2015-11-18 |
2019-01-31 |
Formycon Ag |
Envase farmacéutico precargado que comprende una formulación líquida de un antagonista del vegf.
|
WO2018218013A2
(en)
|
2017-05-24 |
2018-11-29 |
Sio2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
BR112018010005A2
(pt)
|
2015-11-18 |
2018-11-21 |
Formycon Ag |
seringa pré-carregada, e, kit
|
US20180371093A1
(en)
|
2015-12-17 |
2018-12-27 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
US10576128B2
(en)
|
2016-01-26 |
2020-03-03 |
Formycon Ag |
Liquid formulation of a VEGF antagonist
|
JP7503887B2
(ja)
|
2016-04-15 |
2024-06-21 |
ジェネンテック, インコーポレイテッド |
がんを監視及び治療するための方法
|
CN109154027A
(zh)
|
2016-04-15 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
用于监测和治疗癌症的方法
|
WO2017209519A1
(en)
|
2016-05-31 |
2017-12-07 |
Mogam Institute For Biomedical Research |
Ab6 family designer ligands of tgf-beta superfamily
|
CN109690315A
(zh)
|
2016-07-08 |
2019-04-26 |
豪夫迈·罗氏有限公司 |
人附睾蛋白4(he4)用于评估muc16阳性癌症治疗的响应性的用途
|
EP3481963A1
(de)
|
2016-07-08 |
2019-05-15 |
Genentech, Inc. |
Verfahren zur diagnose und behandlung von krebs mittels des expressionsstatus und mutationsstatus von nrf2 und nachgeschalteten zielgenen dieses gens
|
BR112019002036A2
(pt)
|
2016-08-12 |
2019-05-14 |
Genentech Inc |
métodos de tratamento de um sujeito com câncer colorretal, kit para tratamento do câncer colorretal em um sujeito humano e combinação de fármacos para a terapia do câncer colorretal
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
US10603358B2
(en)
|
2017-01-10 |
2020-03-31 |
Nodus Therapeutics |
Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator
|
CN110546277B
(zh)
|
2017-03-01 |
2024-06-11 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
WO2018217995A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
CN110785187B
(zh)
|
2017-06-22 |
2024-04-05 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
EP3642240A1
(de)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antikörpermoleküle gegen cd73 und verwendungen davon
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
JP7021356B2
(ja)
|
2017-12-21 |
2022-02-16 |
ヘフェイ インスティテューツ オブ フィジカル サイエンス, チャイニーズ アカデミー オブ サイエンシーズ |
ピリミジン誘導体系キナーゼ阻害剤類
|
WO2019129677A1
(en)
|
2017-12-29 |
2019-07-04 |
F. Hoffmann-La Roche Ag |
Anti-vegf antibodies and methods of use
|
CN111989095A
(zh)
|
2018-04-16 |
2020-11-24 |
上海岸阔医药科技有限公司 |
预防或治疗肿瘤疗法副作用的方法
|
JOP20200303A1
(ar)
|
2018-05-24 |
2020-11-23 |
Janssen Biotech Inc |
عوامل ربط psma واستخداماتها
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
JP2022512744A
(ja)
|
2018-10-18 |
2022-02-07 |
ジェネンテック, インコーポレイテッド |
肉腫様腎臓がんのための診断および治療方法
|
BR112021020532A2
(pt)
|
2019-04-19 |
2022-03-15 |
Janssen Biotech Inc |
Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3
|
WO2020226986A2
(en)
|
2019-05-03 |
2020-11-12 |
Genentech, Inc. |
Methods of treating cancer with an anti-pd-l1 antibody
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
US20220395553A1
(en)
|
2019-11-14 |
2022-12-15 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
JP2023517345A
(ja)
|
2020-03-13 |
2023-04-25 |
ジェネンテック, インコーポレイテッド |
抗インターロイキン-33抗体及びその使用
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
KR20230033647A
(ko)
|
2020-06-30 |
2023-03-08 |
멘두스 비.브이. |
난소암 백신에서 백혈병 유래 세포의 용도
|
KR20230088781A
(ko)
|
2020-11-13 |
2023-06-20 |
제넨테크, 인크. |
고형 종양 치료를 위한 krasg12c 억제제 및 vegf 억제제를 포함하는 방법 및 조성물
|
US20220249639A1
(en)
|
2021-01-22 |
2022-08-11 |
Dcprime B.V. |
Methods of tumor vaccination
|
MX2023008909A
(es)
|
2021-01-28 |
2023-10-23 |
Janssen Biotech Inc |
Proteínas de unión a psma y usos de estas.
|
WO2022190058A1
(en)
|
2021-03-12 |
2022-09-15 |
Dcprime B.V. |
Methods of vaccination and use of cd47 blockade
|
JP2024516230A
(ja)
|
2021-04-30 |
2024-04-12 |
ジェネンテック, インコーポレイテッド |
がんのための治療及び診断方法並びに組成物
|
WO2023279092A2
(en)
|
2021-07-02 |
2023-01-05 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
EP4377351A1
(de)
|
2021-07-28 |
2024-06-05 |
F. Hoffmann-La Roche AG |
Verfahren und zusammensetzungen zur behandlung von krebs
|
WO2023080900A1
(en)
|
2021-11-05 |
2023-05-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating kidney cancer
|
WO2023212298A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Bispecific antibodies and methods of treating ocular disease
|